Status:
COMPLETED
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
Lead Sponsor:
Pfizer
Conditions:
Aspergillosis
Candidemia
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
Eligibility Criteria
Inclusion
- Healthy adult subjects willing to comply with the study requirement.
Exclusion
- Clinical significant disease.
- Sensitive to study medication.
- Not willing to comply with the study requirement.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00940017
Start Date
September 1 2008
End Date
October 1 2008
Last Update
February 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hartford, Connecticut, United States, 06102